The Multiple Sclerosis Market is projected to grow from $23.65 billion to $33.66 billion, at a CAGR of 4% during the forecast period 2021-2030.
Multiple sclerosis is a chronic inflammatory, immune-mediated disease that affects nerve cells in the spinal cord and brain, leading to demyelination, axotomy, and neurodegeneration. Injections, oral and infusion medications, muscle relaxants, antidepressants, and physical therapy are some of the most popular treatments. Interferon-beta and glatiramer acetate are injection therapies administered subcutaneously or intramuscularly.
Oral medications include teriflunomide, dimethyl fumarate, and cladribine. These treatments include ocrelizumab, alemtuzumab, and natalizumab. The growing base of the target population suffering from relapsing remission and secondary progressive multiple sclerosis along with the growing demand for new potent drugs are key factors driving the Multiple Sclerosis Market growth.
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. It is characterized by a wide range of symptoms, including fatigue, numbness or weakness in limbs, difficulty with coordination and balance, problems with vision, and cognitive impairments. Early diagnosis is crucial, as prompt identification of multiple sclerosis symptoms can lead to timely treatment interventions. Currently, there is no cure for MS, but various treatment options are available to manage the symptoms and slow down the progression of the disease. These treatment approaches include medications to reduce inflammation and modulate the immune system, physical and occupational therapy to improve mobility and function, and lifestyle modifications to promote overall well-being. Regular monitoring and collaboration with healthcare professionals are essential in developing personalized treatment plans for individuals with multiple sclerosis.
Market Dynamics:
Drivers:
Neurotherapy research and development have always been brisk over the past decade. A variety of novel molecules are being investigated for the treatment of multiple sclerosis. Some of the major pharmaceutical companies emphasize improving the disorders associated with multiple sclerosis. Several companies' pipeline portfolios contain agents with different mechanisms of action, which is expected to increase the demand for physicians targeting changes in treatment algorithms in the future. These features are likely to boost the growth of the Multiple Sclerosis Market.
Restraints:
Despite increased government intervention and various treatment options for multiple sclerosis, drug cost remains a significant challenge to market growth. The high cost of medicines makes it inefficient to address the unmet needs of the affected population. This is a major concern and is anticipated to hamper the Multiple Sclerosis Market growth.
Opportunities:
The global burden of multiple sclerosis is growing at an alarming rate and is a concern for healthcare providers and governments. As the spread of the disease increases, governments in many countries have had to take precautions through guidelines and recommendations. In addition to this, various awareness initiatives are being launched by government associations to educate patients about different treatment options. These factors are contributing to bringing many opportunities in this market.
Key Players:
-
F. Hoffmann-La Roche Ltd.
-
Mylan N.V.
-
Teva Pharmaceutical Industries Ltd.
-
Sanofi
-
Pfizer Inc.
-
GlaxoSmithKline plc
-
Novartis AG
-
Eli Lilly and Company
-
Merck & Co., Inc.
-
Allergan
-
AstraZeneca
-
Johnson & Johnson
-
Cipla Inc.
-
Abbott
-
AbbVie Inc.
-
Actelion Pharmaceuticals Ltd
-
Opexa Therapeutics, Inc.
-
Bayer AG
Market Segmentation:
Multiple Sclerosis Market, By Type of Drug
-
Immunomodulators
-
Immunosuppressants
-
Interferons
-
Others
Multiple Sclerosis Market, By Administration Route
-
Oral
-
Injectable
Multiple Sclerosis Market, By Sales Channel
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online Pharmacy
Multiple Sclerosis Market, By Region Type
-
North America
-
Europe
-
Asia-Pacific
-
LAMEA
Regional Analysis:
North America dominated the multiple sclerosis market with revenues of over USD XX billion in 2021. It is anticipated to be the largest region in this market. Higher diagnostic rates in the United States subsequently led to higher prescription rates, which helped the North American market dominate. In 2021, more than XX% of Copaxone medicines’ sales occurred in the United States.
The Asia Pacific market is the most lucrative due to the existence of many future growth opportunities. It is regarded to be the fastest-growing region in this market. High presence of unmet needs coupled with growth in infrastructure will propel growth over the forecast period. Key players to capitalize on these growth opportunities are contracting with local pharmaceutical manufacturers.
Scope of the report:
Report Coverage |
Details |
Base year |
2021 |
Forecast period |
2030 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4% |
YoY growth (%) |
XX% |
Regional analysis |
The Middle East, Europe, North America, Latin America, Asia Pacific, and Africa |
Current Market size |
USD 23.65 Billion |
Forecast market growth |
USD 33.66 Billion |
User
Tab Content
Introduction
Our market research is an extensive, iterative process that takes into account a combination of primary and secondary research tools with the aim of minimizing deviation and producing the most precise estimate and prediction. For the future course of action, this approach meticulously outlines the actual changes and industry trends. It gives incredibly valuable data that is drawn from the insights and opinions of analysts and professionals. Our papers include in-depth research and analysis based on several factual inputs obtained from expert interviews, accurate data, and local information.

Market Size Estimation
The overall size of the market has been estimated and validated using both top-down and bottom-up methods. The sizes of other market subsegments have also been thoroughly estimated using these methodologies.

In the top-down technique, the market is divided into segments based on the percentage share of each segment. This method assisted in determining the size of each segment's market. The market size of each segment and its sub-segments was then divided into regional market sizes. This Approach helps mainly with the new Product Launch. It uses Multi-variate Regression Model coupled with Vendor based primary research inputs to forecast to the Market Size.
In the Bottom-Up approach, comprehensive study of key players has to be done wherein we add the market size of the major key players to understand the national market size which helps to determine the regional market size and eventually the complete market size. Companies annual report along with data from paid and unpaid resources like reports from government agencies and organizations like world bank provide the data for this approach.
Avail 25% Discount
Report Benefits
-
Free Customization Available
-
30% discount on your next purchase
-
Dedicated account manager
-
Query resolution within 24 hours
-
Permission to print the report